MedPath

ew tumor marker for early detection of hepatocellular carcinoma (HCC)

Not Applicable
Conditions
Apply to basic benefits in screening people at high risk of liver cell cancer at the national level
PIVKA&#45
II
AFP&#45
L3
Registration Number
TCTR20200313001
Lead Sponsor
one
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
1080
Inclusion Criteria

1. Patients aged 18 years and older
2. The annual health check-up who has regular blood tests including high frequency sound tests and no lumps suspected of primary liver cancer
3. Chronic hepatitis B patients Males aged over 40 years and females aged over 50 or have direct relatives with primary liver cancer
4.Chronic hepatitis C patients with pathological effects of liver tissue With at least level 3 fascia Or the flexibility of the liver with transient elastography greater than or equal to 9.5 or blood Fibrotest® is greater than 0.58 regardless of whether it has been treated or not.
5. Patients who have been diagnosed with liver cirrhosis for any reason From the examination of high frequency sound waves Radiographic images using a computer or an X-ray of the upper abdomen.
6. Patients who have detected a lump in the liver greater than or equal to 1 cm in size from the ultrasound Radiographic images using a computer or an X-ray of the upper abdomen.

Exclusion Criteria

1. pregnant patients
2. Patients with jaundice from biliary tract obstruction
3. Patients who received vitamin K during the study
4. Patients receiving warfarin While studying
5. Other types of cancer detected While diagnosing primary liver cancer

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary liver cancer diagnosis 3 year PIVKA-II Test µTASWako i30, ELECSYS, ARCHITECT AFP-L3
Secondary Outcome Measures
NameTimeMethod
/A N/A N/A
© Copyright 2025. All Rights Reserved by MedPath